Tsuda H, Sata M, Kumabe T, Hara H, Eriguchi N, Sugita Y, Nagamatsu H
Department of Anesthesiology, Kurume University, School of Medicine, 67 Asahimachi, Kurumeshi, Fukuokaken, 830, Japan.
Oncol Rep. 1998 May-Jun;5(3):597-600. doi: 10.3892/or.5.3.597.
Antineoplastons A10 and AS2-1 exhibit growth inhibition of cancer cells by diverse modes of action. We observed antitumor responses within 2-3 weeks of a combination treatment of chemoradiation therapy and antineoplastons A10 and AS2-1 in phase I clinical study being conducted in Kurume University Hospital. We reviewed 3 clinical cases of advanced cancer (multiple metastatic lung cancer, thalamic glioma and primary lung cancer) in which we believed antineoplaston A10 and AS2-1 may be contributing to the rapid antitumor response. The possible use of this combination for induction therapy in advanced cancer is discussed.
